Interleukin 17A (IL-17A)
IL17A encodes interleukin-17A, a proinflammatory cytokine produced primarily by Th17 cells and other adaptive immune populations.
IL17A encodes interleukin-17A, a proinflammatory cytokine produced primarily by Th17 cells and other adaptive immune populations. It is a central mediator of mucosal immunity and host defense, but it is also strongly implicated in chronic inflammatory and autoimmune disease. IL-17A acts by promoting the expression of downstream inflammatory mediators, chemokines, and tissue-remodeling factors, thereby amplifying immune-cell recruitment and local inflammation. In recent biomedical literature, IL-17A is repeatedly discussed alongside interferon gamma (IFNG), Interleukin-6 (IL-6), tumor necrosis factor alpha, nuclear factor kappa B, and related pathways that shape inflammatory signaling.
Clinically, IL-17A is an important biomarker and therapeutic target. Neutralization of IL-17A, alone or together with IL-17F, has been used in inflammatory diseases such as plaque psoriasis, and IL-17A signaling is also being investigated in inflammatory bowel disease, autoimmune hepatitis, arthritis, uveitis, kidney injury, melanoma brain metastases, infectious disease responses, and fibrosis. Because IL-17A sits at the intersection of protective immunity and pathogenic inflammation, it is frequently studied both as a readout of immune activation and as a mechanistic driver of disease.
Where the papers sit
14 papers from the last 6 months study Interleukin 17A (IL-17A) directly · updated from PubMed 15 Nov 2026
Study type 2 clinical trials · 2 observational · 2 human data · 7 preclinical · 1 unclassified
Themes 3 themes
-
IL-17A Across Disease Pathways
IL-17A is being investigated as a shared inflammatory signal across malignancy, allergic disease, thrombosis and tissue injury. PTGS2/NLRP3 activation recurs in leukemia, while STAT3/IL-17A/NF-κB signaling appears in allergic rhinitis and endothelial activation in cancer-associated thrombosis. Other work connects IL-17A with obesity-driven leukemia, diabetic eye inflammation and parasitic liver lesions. The set lacks a single clinical direction or unified disease question.
8 papers · 57.1%
-
IL-17 Blockade in Inflammation
IL-17 blockade is being extended across giant cell arteritis, polymyalgia rheumatica and immunoglobulin A nephropathy. Secukinumab is being evaluated alongside glucocorticoids for arteritis and polymyalgia rheumatica. Bimekizumab is linked to kidney-function recovery in an immunoglobulin A nephropathy case. Whether these agents can deliver durable steroid-sparing control remains open.
3 papers · 21.4%
-
Bimekizumab in Psoriasis
Bimekizumab is being established as a durable treatment for chronic plaque and palmoplantar psoriasis in routine practice. Real-world studies focus on effectiveness, safety and drug survival over two years, including patients previously exposed to biologics. The recurring question is whether response is maintained across treatment histories and difficult disease sites. Complementary preclinical work points to gut-derived genistein, CD200 and NF-κB inhibition as possible routes to suppress psoriatic inflammation.
3 papers · 21.4%
Papers
The 14 papers from the last 6 months that study Interleukin 17A (IL-17A) directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
IL-17A Across Disease Pathways (8)
- Identification of vaccine candidates by immunization with a complex pool of recombinant VLPs. Vaccine · 13 Aug 2026 PMID 42594642
- Interleukin-17A: a novel player in the treatment of liver lesions associated with cystic echinococcosis. Journal of helminthology · 10 Aug 2026 PMID 42572858
- Mechanism of Compound Xinyi Nasal Drops in the Treatment of Allergic Rhinitis Through STAT3/IL-17A/NF-κB Signaling Pathway Based on Network Pharmacology and Experimental Verification. Biomedical chromatography : BMC · 6 Jul 2026 PMID 42409592
- Levels of DEL-1 and IL-17 in the aqueous humor of cataract patients with diabetes without diabetic retinopathy. International ophthalmology · 25 Jun 2026 PMID 42347979
- Targeting GLP-1R and IL-17A suppresses obesity-induced leukemia in an oncogenic PTPN11 mutation-driven model. The Journal of clinical investigation · 23 Jun 2026 PMID 42334870
- Plasma proteomics improves thrombosis prediction in patients with cancer and identifies targetable IL-17-driven endothelial activation. Science translational medicine · 17 Jun 2026 PMID 42308329
- Plasticizer-responsive molecular axes in heart failure: a subtype-aware toxicogenomic framework relevant to environmental health. Environment international · 3 Jun 2026 PMID 42235321
- Therapeutic targeting of IL-17A-driven PTGS2/NLRP3 inflammasome activation in juvenile myelomonocytic leukemia. Blood · 3 Jun 2026 PMID 42233403
IL-17 Blockade in Inflammation (3)
- Kidney function recovery in immunoglobulin A nephropathy patient following bimekizumab therapy. BMJ case reports · 23 Jul 2026 PMID 42493217
- Phase 3 Trial of Secukinumab in Polymyalgia Rheumatica. The New England journal of medicine · 3 Jun 2026 PMID 42234540
- Secukinumab for Giant Cell Arteritis. NEJM evidence · 3 Jun 2026 PMID 42234457
Bimekizumab in Psoriasis (3)
- Effectiveness of bimekizumab according to previous biologic exposure in patients with plaque psoriasis: a multicenter real-world study. The Journal of dermatological treatment · 29 Jul 2026 PMID 42522774
- Gut-derived genistein from Parabacteroides distasonis alleviates psoriatic inflammation via CD200-mediated NF-κB inhibition in mice. Gut microbes · 16 Jul 2026 PMID 42461117
- Effectiveness, Safety, and Drug Survival of Bimekizumab in Chronic Plaque Psoriasis over 2 Years: Real-World Experience from Northern Italy. Dermatology and therapy · 28 Jun 2026 PMID 42366325
By study type
Clinical trials (2)
- Phase 3 Trial of Secukinumab in Polymyalgia Rheumatica. The New England journal of medicine · 3 Jun 2026 PMID 42234540
- Secukinumab for Giant Cell Arteritis. NEJM evidence · 3 Jun 2026 PMID 42234457
Observational studies and case reports (2)
- Effectiveness of bimekizumab according to previous biologic exposure in patients with plaque psoriasis: a multicenter real-world study. The Journal of dermatological treatment · 29 Jul 2026 PMID 42522774
- Kidney function recovery in immunoglobulin A nephropathy patient following bimekizumab therapy. BMJ case reports · 23 Jul 2026 PMID 42493217
Human data, design not indexed (2)
- Levels of DEL-1 and IL-17 in the aqueous humor of cataract patients with diabetes without diabetic retinopathy. International ophthalmology · 25 Jun 2026 PMID 42347979
- Plasticizer-responsive molecular axes in heart failure: a subtype-aware toxicogenomic framework relevant to environmental health. Environment international · 3 Jun 2026 PMID 42235321
Preclinical: animal, cell and lab studies (7)
- Identification of vaccine candidates by immunization with a complex pool of recombinant VLPs. Vaccine · 13 Aug 2026 PMID 42594642
- Interleukin-17A: a novel player in the treatment of liver lesions associated with cystic echinococcosis. Journal of helminthology · 10 Aug 2026 PMID 42572858
- Gut-derived genistein from Parabacteroides distasonis alleviates psoriatic inflammation via CD200-mediated NF-κB inhibition in mice. Gut microbes · 16 Jul 2026 PMID 42461117
- Mechanism of Compound Xinyi Nasal Drops in the Treatment of Allergic Rhinitis Through STAT3/IL-17A/NF-κB Signaling Pathway Based on Network Pharmacology and Experimental Verification. Biomedical chromatography : BMC · 6 Jul 2026 PMID 42409592
- Targeting GLP-1R and IL-17A suppresses obesity-induced leukemia in an oncogenic PTPN11 mutation-driven model. The Journal of clinical investigation · 23 Jun 2026 PMID 42334870
- Plasma proteomics improves thrombosis prediction in patients with cancer and identifies targetable IL-17-driven endothelial activation. Science translational medicine · 17 Jun 2026 PMID 42308329
- Therapeutic targeting of IL-17A-driven PTGS2/NLRP3 inflammasome activation in juvenile myelomonocytic leukemia. Blood · 3 Jun 2026 PMID 42233403
Unclassified: not yet indexed with MeSH (1)
- Effectiveness, Safety, and Drug Survival of Bimekizumab in Chronic Plaque Psoriasis over 2 Years: Real-World Experience from Northern Italy. Dermatology and therapy · 28 Jun 2026 PMID 42366325
Written from 14 PubMed abstracts, each one listed by PMID above. Published: 2026-06-16. Last written: 2026-08-26 by GPT. Drafted by language models from published abstracts; not medical advice.